@vintage your 3rd paragraph follows an absurd line of argumentation.
By the way I looked at the DXB-200 FSGS trial description on clinical trials.gov. Pregnant women excluded. Patients with liver enzymes above twice the upper limit of normal excluded. Patients with heart failure grade 3/4 excluded. Are there some safety risks with DXB-200 that we haven't been told about (for example from animal studies) that made DXB insert those conditions into the trial?
And your 150 number- it's a 50:50 placebo controlled trial . So the actual number getting DXB200 is 75 so far. That is a fraction (<10%) of the entire clinical trial evidence base for sparsentan (across both diseases FSGS and IgA ).
Let's see how this all eventually plays out. All that matters is the data, not what people hope to be true.
DXB Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)